Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
A league of Liberal Democratic Party (LDP) lawmakers promoting HPV vaccinations on June 9 adopted a resolution calling for the inclusion of HPV vaccinations for males in Japan’s national immunization program (NIP) by April 2027. The group, chaired by former…
To read the full story
Related Article
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
- LDP Group Renews Call for Gender-Neutral HPV Vaccination
July 9, 2024
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
- Lawmakers Request 4-Valent HPV Vaccination Program for Males to Minister
November 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
REGULATORY
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
- Japan Eyes Early FY2027 Rollout of RSV Antibodies under NIP: Minister
July 21, 2026
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…